JP6670235B2 - 可逆的ヘパリン分子、その製法及びその使用方法 - Google Patents

可逆的ヘパリン分子、その製法及びその使用方法 Download PDF

Info

Publication number
JP6670235B2
JP6670235B2 JP2016521505A JP2016521505A JP6670235B2 JP 6670235 B2 JP6670235 B2 JP 6670235B2 JP 2016521505 A JP2016521505 A JP 2016521505A JP 2016521505 A JP2016521505 A JP 2016521505A JP 6670235 B2 JP6670235 B2 JP 6670235B2
Authority
JP
Japan
Prior art keywords
ost
sulfotransferase
heparin
paps
substrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016521505A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016523535A5 (enExample
JP2016523535A (ja
Inventor
リウ ジエン
リウ ジエン
シュウ ヤングメイ
シュウ ヤングメイ
ジェイ リンハート ロバート
ジェイ リンハート ロバート
ハリス エドワード
ハリス エドワード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of JP2016523535A publication Critical patent/JP2016523535A/ja
Publication of JP2016523535A5 publication Critical patent/JP2016523535A5/ja
Application granted granted Critical
Publication of JP6670235B2 publication Critical patent/JP6670235B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/10—Heparin; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/18—Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Materials Engineering (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Sustainable Development (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2016521505A 2013-06-17 2014-06-17 可逆的ヘパリン分子、その製法及びその使用方法 Active JP6670235B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361835875P 2013-06-17 2013-06-17
US61/835,875 2013-06-17
PCT/US2014/042683 WO2014204929A2 (en) 2013-06-17 2014-06-17 Reversible heparin molecules and methods of making and using the same

Publications (3)

Publication Number Publication Date
JP2016523535A JP2016523535A (ja) 2016-08-12
JP2016523535A5 JP2016523535A5 (enExample) 2017-08-03
JP6670235B2 true JP6670235B2 (ja) 2020-03-18

Family

ID=52105487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016521505A Active JP6670235B2 (ja) 2013-06-17 2014-06-17 可逆的ヘパリン分子、その製法及びその使用方法

Country Status (6)

Country Link
US (1) US9951149B2 (enExample)
EP (1) EP3011043B1 (enExample)
JP (1) JP6670235B2 (enExample)
CN (1) CN105452479B (enExample)
ES (1) ES2924830T3 (enExample)
WO (1) WO2014204929A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11203772B2 (en) 2010-12-23 2021-12-21 The University Of North Carolina At Chapel Hill Chemoenzymatic synthesis of structurally homogeneous ultra-low molecular weight heparins
US11633424B2 (en) 2018-06-20 2023-04-25 The University Of North Carolina At Chapel Hill Cell protective methods and compositions
US11865137B2 (en) 2017-11-03 2024-01-09 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
US11903963B2 (en) 2017-03-10 2024-02-20 The University Of North Carolina At Chapel Hill Short-acting heparin-based anticoagulant compounds and methods
US11993627B2 (en) 2017-07-03 2024-05-28 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3011043B1 (en) 2013-06-17 2022-05-11 The University of North Carolina At Chapel Hill Reversible heparin molecules
EP3273239A1 (en) * 2016-07-19 2018-01-24 Laboratorios Farmacéuticos Rovi, S.A. Procedure of analysis of glycosaminoglycans, heparins and their derivatives by nuclear magnetic resonance
TWI769176B (zh) * 2016-09-07 2022-07-01 瑞瑟勒綜合技術協會 生合成肝素
US10864227B2 (en) 2017-03-20 2020-12-15 Rensselaer Polytechnic Institute Enzymatic preparation of increased anticoagulant bovine sourced heparin
EP3723862A4 (en) * 2017-12-12 2021-08-25 Academia Sinica OCTASACCHARIDES AND THEIR USES
TW201937167A (zh) * 2018-03-01 2019-09-16 中央研究院 用來偵測癌細胞的裝置及方法
CN109321508B (zh) * 2018-10-12 2022-12-27 北京化工大学 产heparosan的基因工程菌及其应用
MX2021008479A (es) 2019-01-15 2021-10-13 Optimvia Llc Enzimas dependientes de aril sulfato modificadas por ingenieria genetica.
WO2022015794A1 (en) 2020-07-14 2022-01-20 Optimvia, Llc Methods for synthesizing non-anticoagulant heparan sulfate
CA3144968A1 (en) 2019-07-09 2021-01-14 Optimvia Llc Methods for synthesizing anticoagulant polysaccharides
CN111154819B (zh) * 2020-01-15 2022-08-30 山东大学 一种非动物源低分子量肝素及其制备方法与应用
CN113583151B (zh) * 2021-07-07 2023-06-20 山东大学 含at结合序列和连续2-o-葡糖醛酸残基的肝素分子及其制备方法与应用
CN113564139B (zh) * 2021-08-02 2023-03-10 山东大学 巴氏杆菌肝素骨架合酶BtHS1及其突变体与应用
CN116120484B (zh) * 2022-09-01 2024-11-08 山东大学 一种抗凝血肝素寡糖苯联二聚体及其制备方法与应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4865870A (en) 1988-07-07 1989-09-12 Becton, Dickinson And Company Method for rendering a substrate surface antithrombogenic
PT93847A (pt) 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
US5378829A (en) 1990-04-23 1995-01-03 Akzo N.V. Sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type
IT1260137B (it) 1992-04-17 1996-03-28 Alfa Wassermann Spa Glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2 dell'acido alfa-l-iduronico-2-0-solfato
JP3818676B2 (ja) 1994-07-22 2006-09-06 生化学工業株式会社 ヘパラン硫酸６−ｏ−硫酸基転移酵素
IT1271057B (it) 1994-11-04 1997-05-26 Inalco Spa Polisaccaridi aventi un elevato contenuto di acido iduronico
JP3672359B2 (ja) 1995-07-24 2005-07-20 生化学工業株式会社 ヘパラン硫酸 ２−ｏ−硫酸基転移酵素
US5935824A (en) 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
US6861254B1 (en) 1997-10-24 2005-03-01 Massachusetts Institute Of Technology Heparan sulfate D-glucosaminyl 3-O-sulfotransferases, and uses therefor
US8088604B2 (en) 1998-04-02 2012-01-03 The Board Of Regents Of The University Of Oklahoma Production of defined monodisperse heparosan polymers and unnatural polymers with polysaccharide synthases
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US6255088B1 (en) 1999-05-11 2001-07-03 The Scripps Research Institute Enzymatic sulfation of biomolecules
CA2441984A1 (en) 2001-03-28 2002-10-10 Massachusetts Institute Of Technology Methods of 6-o-sulfating polysaccharides and 6-o-sulfated polysaccharide preparations
WO2002089742A2 (en) * 2001-05-08 2002-11-14 The Board Of Regents Of The University Of Oklahoma Heparin/heparosan synthase and methods of making and using same
PT1401853E (pt) 2001-05-25 2010-12-07 Univ Duke Modulador de oligonucleotídeos
WO2003018598A2 (en) * 2001-08-30 2003-03-06 University College Dublin Monosaccharide derivatives
US7531338B2 (en) 2002-07-05 2009-05-12 The University Of North Carolina At Chapel Hill Purified and isolated heparan sulfate 3-O-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same
GB0216861D0 (en) 2002-07-19 2002-08-28 Univ Birmingham Saccharide libraries
WO2004017910A2 (en) * 2002-08-23 2004-03-04 Neose Technologies, Inc. Total synthesis of heparin
WO2005014619A2 (en) * 2003-03-28 2005-02-17 Thomas Jefferson University Heparin-binding peptides and uses thereof
US7655445B2 (en) 2003-11-12 2010-02-02 Massachusetts Institute Of Technology Methods for synthesis of sulfated saccharides
US20090197308A1 (en) 2005-05-12 2009-08-06 Jian Liu Enzymatic synthesis of sulfated polysaccharides
EP2447285A3 (en) 2006-05-25 2013-01-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
WO2009014715A2 (en) * 2007-07-23 2009-01-29 The University Of North Carolina At Chapel Hill Enzymatic synthesis of sulfated polysaccharides without iduronic acid residues
US8455439B2 (en) 2008-11-14 2013-06-04 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents
US20110054236A1 (en) * 2009-08-25 2011-03-03 The Regents Of The University Of Michigan Compositions and methods for targeting tumors
WO2011038047A1 (en) 2009-09-23 2011-03-31 Momenta Pharmaceuticals, Inc. Methods of treatment with a low molecular weight heparin composition
US11203772B2 (en) * 2010-12-23 2021-12-21 The University Of North Carolina At Chapel Hill Chemoenzymatic synthesis of structurally homogeneous ultra-low molecular weight heparins
WO2012116048A1 (en) * 2011-02-22 2012-08-30 Rensselaer Polytechnic Institute Single step heparosan n-deacetylation and depolymerization for making bioengineered heparin
US8519189B2 (en) 2011-06-01 2013-08-27 University Of British Columbia Polymers for reversing heparin-based anticoagulation
EP3011043B1 (en) 2013-06-17 2022-05-11 The University of North Carolina At Chapel Hill Reversible heparin molecules

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11203772B2 (en) 2010-12-23 2021-12-21 The University Of North Carolina At Chapel Hill Chemoenzymatic synthesis of structurally homogeneous ultra-low molecular weight heparins
US11903963B2 (en) 2017-03-10 2024-02-20 The University Of North Carolina At Chapel Hill Short-acting heparin-based anticoagulant compounds and methods
US11993627B2 (en) 2017-07-03 2024-05-28 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides
US11865137B2 (en) 2017-11-03 2024-01-09 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
US12397016B2 (en) 2017-11-03 2025-08-26 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
US11633424B2 (en) 2018-06-20 2023-04-25 The University Of North Carolina At Chapel Hill Cell protective methods and compositions

Also Published As

Publication number Publication date
CN105452479B (zh) 2021-05-18
CN105452479A (zh) 2016-03-30
US9951149B2 (en) 2018-04-24
ES2924830T3 (es) 2022-10-11
EP3011043A2 (en) 2016-04-27
US20160122446A1 (en) 2016-05-05
WO2014204929A2 (en) 2014-12-24
WO2014204929A3 (en) 2015-10-29
JP2016523535A (ja) 2016-08-12
EP3011043B1 (en) 2022-05-11
EP3011043A4 (en) 2017-01-18

Similar Documents

Publication Publication Date Title
JP6670235B2 (ja) 可逆的ヘパリン分子、その製法及びその使用方法
US8771995B2 (en) Enzymatic synthesis of sulfated polysaccharides
US11203772B2 (en) Chemoenzymatic synthesis of structurally homogeneous ultra-low molecular weight heparins
AU2006311794B2 (en) Heparan sulfate glycosaminoglycan lyase and uses thereof
US8088604B2 (en) Production of defined monodisperse heparosan polymers and unnatural polymers with polysaccharide synthases
US20090035787A1 (en) Enzymatic synthesis of sulfated polysaccharides without iduronic acid residues
US11629364B2 (en) Methods for synthesizing anticoagulant polysaccharides
US8198050B2 (en) Heparan sulfate glycosaminoglycan lyase and uses thereof
US20080108110A1 (en) Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
Habuchi et al. Biosynthesis of heparan sulfate and heparin how are the multifunctional glycosaminoglycans built up?
Class et al. Patent application title: REVERSIBLE HEPARIN MOLECULES AND METHODS OF MAKING AND USING THE SAME Inventors: Jian Liu (Chapel Hill, NC, US) Yongmei Xu (Durham, NC, US) Robert J. Linhardt (Albany, NY, US) Robert J. Linhardt (Albany, NY, US) Edward Harris (Lincoln, NE, US)
AU2013237670B2 (en) Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
US7691613B2 (en) Glycosaminoglycan lyase IV and uses thereof
JP2002327002A (ja) 硫酸基を有するオリゴ糖
AU2007351891A1 (en) Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181012

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20181012

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200228

R150 Certificate of patent or registration of utility model

Ref document number: 6670235

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250